5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Asia-Pacific Veterinary Healthcare market is segmented by Product, Animal Type, and Geography
The Asia Pacific veterinary healthcare market is projected to have significant growth owing to increasing risk of emerging zoonosis and rising awareness regarding the animal health in Asia Pacific. Other factors responsible for the growth of the market studied include an increase in the number of farm animals and growing technological advancements in animal healthcare.
According to the National Dairy Development Board, in 2017, in India, the cattle population was valued at 156.7 million and the nation has one of the largest animal husbandry sectors in the world, along with the largest livestock population (520.6 million). However, the use of counterfeit medicines, lack of infrastructure, and funding are restraining the growth of the market studied.
As per the scope of this report, the AsiaPacific veterinary healthcare market comprises of therapeutic and diagnostic products and solutions for companion and farm animals. Companion animals can be tamed or adopted for companionship or as house/office guards, and farm animals are raised for meat and milk-related products. Companion animals include canine, feline, and equine. Farm animals are bovine, poultry, and porcine.
|By Animal Type|
|Dogs and Cats|
Report scope can be customized per your requirements. Click here.
To understand key trends, Download Sample Report
The players in the Asia-Pacific veterinary healthcare market are primarily focusing on various growth strategies, such as collaborations, partnerships, agreements, mergers, and acquisitions, in order to enhance their market presence. Major market players include Bayer Healthcare, Boehringer Ingelheim, Ceva Animal Health, Inc., Elanco, Merck Animal Health, and Zoetis and Virbac Corporation, among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.1.1 Advanced Technology is Leading to Innovations in Animal Healthcare
4.1.2 Increasing Productivity at the Risk of Emerging Zoonosis
4.2 Market Restraints
4.2.1 Increasing Cost of Animal Testing and Veterinary Services
4.2.2 Lack of Infrastructure and Funding
4.2.3 Use of Counterfeit Medicines
4.3 Porter's Five Forces Analysis
4.3.1 Threat of New Entrants
4.3.2 Bargaining Power of Buyers/Consumers
4.3.3 Bargaining Power of Suppliers
4.3.4 Threat of Substitute Products
4.3.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 By Therapeutics
18.104.22.168 Medical Feed Additives
22.214.171.124 Other Therapeutics
5.1.2 By Diagnostics
126.96.36.199 Immunodiagnostic Tests
188.8.131.52 Molecular Diagnostics
184.108.40.206 Diagnostic Imaging
220.127.116.11 Clinical Chemistry
18.104.22.168 Other Diagnostics
5.2 By Animal Type
5.2.1 Dogs and Cats
5.2.6 Other Animals
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co., Inc.
6.1.5 Bayer AG
6.1.6 ceva Santé Animale
6.1.8 IDEXX Laboratories
6.1.9 Phibro Animal Health
6.1.10 Boehringer Ingelheim
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers - Business Overview, Financials, Products and Strategies, and Recent Developments